| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
45,640,000 |
| Market
Cap: |
101.78(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.53 - $2.26 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. Co.'s U.S. Food and Drug Administration approved commercial product, NUZYRA®, is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA®, is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
788,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,282,057 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
142,346 |
584,838 |
| Total Sell Value |
$0 |
$0 |
$313,161 |
$1,304,750 |
| Total People Sold |
0 |
0 |
4 |
7 |
| Total Sell Transactions |
0 |
0 |
4 |
30 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oclassen Glenn A |
President and CEOOfficer |
• • – |
2009-01-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
- |
|
| Singh Nikhilesh N |
SVP & Chief Scientific Officer |
• – – |
2009-01-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
60 |
|
- |
|
| Singh Nikhilesh N |
SVP & Chief Scientific Officer |
• – – |
2009-01-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
200 |
|
- |
|
| Laporte Kathleen |
Director |
– • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,636,982 |
1,636,982 |
|
- |
|
| Ehrlich Christopher B |
Director |
– • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,251,808 |
1,251,808 |
|
- |
|
| Turner Daniel K III |
Director |
– • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,305,342 |
67,232 |
|
- |
|
| Raab G Kirk |
Director |
– • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
118,584 |
118,584 |
|
- |
|
| Kiley Thomas |
Director |
– • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
20,369 |
20,369 |
|
- |
|
| Kiley Thomas |
Director |
– • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
31,660 |
31,660 |
|
- |
|
| Singh Nikhilesh N |
SVP & Chief Scientific Officer |
• – – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
115,150 |
36,709 |
|
- |
|
| Singh Nikhilesh N |
SVP & Chief Scientific Officer |
• – – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
13,237 |
13,437 |
|
- |
|
| Soloway Thomas P |
SVP, Operations and CFO |
• – – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
28,995 |
20,833 |
|
- |
|
| Soloway Thomas P |
SVP, Operations and CFO |
• – – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,239 |
2,239 |
|
- |
|
| Oclassen Glenn A |
President and CEO |
• • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
57,457 |
63,457 |
|
- |
|
| Oclassen Glenn A |
President and CEO |
• • – |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
26,647 |
28,647 |
|
- |
|
| Kramlich C Richard |
10% Owner |
– – • |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,103,283 |
1,103,283 |
|
- |
|
| Perry Mark W |
10% Owner |
– – • |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,103,283 |
1,103,283 |
|
- |
|
| Barrett M James |
10% Owner |
– – • |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,103,283 |
1,103,283 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,103,283 |
1,103,283 |
|
- |
|
| Newhall Charles W III |
10% Owner |
– – • |
2009-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,103,283 |
1,103,283 |
|
- |
|
| Schoemaker Kathleen K |
10% Owner |
– – • |
2009-01-30 |
4 |
S |
$0.98 |
$147,294 |
I/I |
(150,300) |
67,875 |
|
- |
|
| Treu Jesse I |
10% Owner |
– – • |
2009-01-30 |
4 |
S |
$0.98 |
$147,294 |
I/I |
(150,300) |
67,875 |
|
- |
|
| Blair James C |
10% Owner |
– – • |
2009-01-30 |
4 |
S |
$0.98 |
$147,294 |
I/I |
(150,300) |
67,875 |
|
- |
|
| Dovey Brian H |
10% Owner |
– – • |
2009-01-30 |
4 |
S |
$0.98 |
$147,294 |
I/I |
(150,300) |
67,875 |
|
- |
|
| Dp V Associates Lp |
10% Owner |
– – • |
2009-01-30 |
4 |
S |
$0.98 |
$3,358 |
D/D |
(3,427) |
67,875 |
|
- |
|
571 Records found
|
|
Page 17 of 23 |
|
|
